Our results indicated the potential of EV COPB2 as a predictive biomarker for COVID‐19 disease severity in both the discovery and validation cohorts and may show utility for improved patient stratification and making early clinical decisions about strategies for COVID‐19 therapy. Here, COPB2 is linked to COVID-19.